KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenet Healthcare (THC) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Tenet Healthcare (THC) over the last 17 years, with Q3 2025 value amounting to $38.0 million.

  • Tenet Healthcare's Share-based Compensation rose 13750.0% to $38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.0 million, marking a year-over-year increase of 4492.75%. This contributed to the annual value of $67.0 million for FY2024, which is 151.52% up from last year.
  • Per Tenet Healthcare's latest filing, its Share-based Compensation stood at $38.0 million for Q3 2025, which was up 13750.0% from $20.0 million recorded in Q2 2025.
  • Tenet Healthcare's 5-year Share-based Compensation high stood at $38.0 million for Q3 2025, and its period low was $9.0 million during Q4 2022.
  • For the 5-year period, Tenet Healthcare's Share-based Compensation averaged around $17.1 million, with its median value being $16.0 million (2021).
  • In the last 5 years, Tenet Healthcare's Share-based Compensation crashed by 3076.92% in 2022 and then skyrocketed by 13750.0% in 2025.
  • Quarter analysis of 5 years shows Tenet Healthcare's Share-based Compensation stood at $13.0 million in 2021, then plummeted by 30.77% to $9.0 million in 2022, then soared by 100.0% to $18.0 million in 2023, then dropped by 16.67% to $15.0 million in 2024, then soared by 153.33% to $38.0 million in 2025.
  • Its Share-based Compensation was $38.0 million in Q3 2025, compared to $20.0 million in Q2 2025 and $21.0 million in Q1 2025.